These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 32702221)

  • 1. Agomelatine for the Treatment of Generalized Anxiety Disorder: A Meta-Analysis.
    Wang SM; Woo YS; Kim NY; Na HR; Lim HK; Bahk WM
    Clin Psychopharmacol Neurosci; 2020 Aug; 18(3):423-433. PubMed ID: 32702221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Remission Rates and Tolerability of Drugs for Generalised Anxiety Disorder: A Systematic Review and Network Meta-analysis of Double-Blind Randomized Controlled Trials.
    Kong W; Deng H; Wan J; Zhou Y; Zhou Y; Song B; Wang X
    Front Pharmacol; 2020; 11():580858. PubMed ID: 33343351
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy of Agomelatine 25-50 mg for the Treatment of Anxious Symptoms and Functional Impairment in Generalized Anxiety Disorder: A Meta-Analysis of Three Placebo-Controlled Studies.
    Stein DJ; Khoo JP; Picarel-Blanchot F; Olivier V; Van Ameringen M
    Adv Ther; 2021 Mar; 38(3):1567-1583. PubMed ID: 33537871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: A 12-week, double-blind, placebo-controlled study.
    Stein DJ; Ahokas A; Jarema M; Avedisova AS; Vavrusova L; Chaban O; Gruget C; Olivier V; Picarel-Blanchot F; de Bodinat C
    Eur Neuropsychopharmacol; 2017 May; 27(5):526-537. PubMed ID: 28298261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duloxetine: a review of its use in the treatment of generalized anxiety disorder.
    Carter NJ; McCormack PL
    CNS Drugs; 2009; 23(6):523-41. PubMed ID: 19480470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: a systematic review and meta-analysis.
    Pae CU; Wang SM; Han C; Lee SJ; Patkar AA; Masand PS; Serretti A
    J Psychiatr Res; 2015 May; 64():88-98. PubMed ID: 25851751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study.
    Stein DJ; Ahokas A; Márquez MS; Höschl C; Oh KS; Jarema M; Avedisova AS; Albarran C; Olivier V
    J Clin Psychiatry; 2014 Apr; 75(4):362-8. PubMed ID: 24569045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25-50 mg/day) versus escitalopram (10-20 mg/day) in out-patients with severe generalized anxiety disorder.
    Stein DJ; Khoo JP; Ahokas A; Jarema M; Van Ameringen M; Vavrusova L; Hӧschl C; Bauer M; Bitter I; Mosolov SN; Olivier V; Matharan S; Picarel-Blanchot F; de Bodinat C
    Eur Neuropsychopharmacol; 2018 Aug; 28(8):970-979. PubMed ID: 30135032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study.
    Stein DJ; Ahokas AA; de Bodinat C
    J Clin Psychopharmacol; 2008 Oct; 28(5):561-6. PubMed ID: 18794654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial.
    Zajecka J; Schatzberg A; Stahl S; Shah A; Caputo A; Post A
    J Clin Psychopharmacol; 2010 Apr; 30(2):135-44. PubMed ID: 20520286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial.
    Stahl SM; Fava M; Trivedi MH; Caputo A; Shah A; Post A
    J Clin Psychiatry; 2010 May; 71(5):616-26. PubMed ID: 20361916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of agomelatine 25-50 mg on functional outcomes in patients with major depressive disorder.
    Kennedy SH; Heun R; Avedisova A; Ahokas A; Olivier V; Picarel-Blanchot F; de Bodinat C
    J Affect Disord; 2018 Oct; 238():122-128. PubMed ID: 29879606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.
    Gelenberg AJ; Lydiard RB; Rudolph RL; Aguiar L; Haskins JT; Salinas E
    JAMA; 2000 Jun; 283(23):3082-8. PubMed ID: 10865302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Profile of agomelatine and its potential in the treatment of generalized anxiety disorder.
    Levitan MN; Papelbaum M; Nardi AE
    Neuropsychiatr Dis Treat; 2015; 11():1149-55. PubMed ID: 25999720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study.
    Stein DJ; Ahokas A; Albarran C; Olivier V; Allgulander C
    J Clin Psychiatry; 2012 Jul; 73(7):1002-8. PubMed ID: 22901350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double-blind, randomized study of extended release quetiapine fumarate (quetiapine XR) monotherapy in older patients with generalized anxiety disorder.
    Mezhebovsky I; Mägi K; She F; Datto C; Eriksson H
    Int J Geriatr Psychiatry; 2013 Jun; 28(6):615-25. PubMed ID: 23070803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial.
    Bidzan L; Mahableshwarkar AR; Jacobsen P; Yan M; Sheehan DV
    Eur Neuropsychopharmacol; 2012 Dec; 22(12):847-57. PubMed ID: 22898365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of short-term duloxetine treatment in adults with generalized anxiety disorder: A meta-analysis.
    Li X; Zhu L; Zhou C; Liu J; Du H; Wang C; Fang S
    PLoS One; 2018; 13(3):e0194501. PubMed ID: 29558528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline.
    Demyttenaere K; Corruble E; Hale A; Quera-Salva MA; Picarel-Blanchot F; Kasper S
    CNS Spectr; 2013 Jun; 18(3):163-70. PubMed ID: 23472671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evaluation of the anxiolytic SC 48,274 in generalized anxiety disorder (GAD).
    Cutler NR; Sramek JJ; Macpherson AE; Doss MG; Benes CO; Howard SF
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 Jul; 18(4):685-94. PubMed ID: 7938559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.